High Incidence Rate in Several US States Offer Opportunity for Market Players
The explosion of whole genome sequencing method anticipate personalized cancer treatment through development of high end sequencing methods along with exponential decline in the cost of sequencing. A significant decline in the cost of whole genome sequencing is likely to generate a potential market of US$5.2 Billion in 2013. The potential for whole genome sequencing help the market players to gauge maximum opportunity for growth.
View full press release